GN Store Nord consensus points to cautious upside, sector peers stay in focus for the stock

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-28, 12:59.

GN Store Nord (DK0010272632) sits in a mid-cap niche between Europe’s larger hearing-care names such as Demant and Sonova, and remains covered by a small but active group of analysts on Nasdaq Copenhagen. Consensus numbers for the current year frame the expectations for the stock.

What analysts currently expect

Most houses that follow GN Store Nord work with full-year revenue projections in the low double-digit billions of Danish kroner, coupled with a mid-teens EBIT margin assumption, according to recent consensus compilations on MarketScreener and similar platforms that aggregate broker estimates. Each data point in these tables represents a dated broker forecast, usually updated after quarterly reports or guidance changes.

The distribution of ratings is mixed but skewed moderately positive, with a slight majority of Buy or Outperform calls over Neutral and only a handful of Underperform ratings. That split reflects cautious upside rather than a strong conviction trade, and it is consistent with the commentary at several European brokers who cite GN’s exposure to structurally growing hearing-aid demand but also competitive pressure from Demant and Sonova as well as macro-sensitive consumer electronics.

How GN Store Nord compares with sector peers

GN Store Nord operates alongside Demant on Nasdaq Copenhagen and Sonova on SIX Swiss Exchange, all of them serving an ageing population that drives steady demand for hearing-care products. Over recent 12-month periods Demant and Sonova shares have generally outperformed GN, a detail that is frequently noted in broker sector reviews as a sign that investors reward scale and diversification.

In those reviews, GN Store Nord is often described as more cyclical because of its audio headsets and consumer-facing product exposure, while Demant and Sonova lean more purely on the medical-technology hearing segment. This relative positioning means GN is sometimes treated by analysts as a higher-beta way to play the same demographic tailwind, with correspondingly more sensitivity to earnings disappointments or execution missteps.

The product behind the stock

GN Store Nord generates its revenue mainly through hearing aids and audio solutions sold under brands such as ReSound and Jabra, targeting both clinical hearing-care channels and consumer electronics retail. The company develops and manufactures devices that combine miniaturized hardware and software to improve speech intelligibility and sound quality for end users.

Where the stock trades today

GN Store Nord shares (DK0010272632) trade on Nasdaq Copenhagen, where they last closed at a price in the mid-hundreds of Danish kroner, with the exact figure varying by trading day and intraday fluctuations in Danish-krone terms.

This article is based on publicly available information and analyst consensus data. It does not contain investment advice, does not recommend buying or selling GN Store Nord shares and does not set any own price targets. Investors should consult professional advisers before making investment decisions.